Abstract
Cerebrovascular diseases and especially ischemic stroke are a leading cause of death. They occur mostly due to an insufficient oxygen (O2) supply to the central neural tissue as a result of thromboembolic events and/or obstructive vessel disease. The primary damage of the brain tissue cannot be restored. However, adequate therapy could minimize secondary impairment of brain tissue and restore neuronal function in the so-called “penumbra region”. Apart from reopening occluded vessels, additional O2 supply is essential for survival of malfunctioning neural tissue. Breathing of 100% O2 under hyperbaric conditions, hyperbaric oxygenation (HBO), is the only method to increase the O2 concentration in tissue with impaired blood supply. Experimental as well as clinical studies have reported a positive effect of HBO therapy. Survival rate has increased under HBO therapy and neurological outcome has improved. The optimal levels of pressure as well as duration and numbers of HBO sessions need to be specified to avoid undesirable effects. Unfortunately, many questions remain unanswered before routinely recommending HBO as additional therapy in clinical practice. In this review we consider the (patho-)physiological background of HBO-therapy, the latest results of experimental and clinical studies and stress the evidence in patients with cerebrovascular disease.
Keywords: Hyperbaric oxygenation, cerebrovascular disease, brain tissue ischemia, penumbra
Current Vascular Pharmacology
Title: Rationale of Hyperbaric Oxygenation in Cerebral Vascular Insult
Volume: 8 Issue: 1
Author(s): Bernhard R. Fischer, Stefan Palkovic, Markus Holling, Johannes Wolfer and Hansdetlef Wassmann
Affiliation:
Keywords: Hyperbaric oxygenation, cerebrovascular disease, brain tissue ischemia, penumbra
Abstract: Cerebrovascular diseases and especially ischemic stroke are a leading cause of death. They occur mostly due to an insufficient oxygen (O2) supply to the central neural tissue as a result of thromboembolic events and/or obstructive vessel disease. The primary damage of the brain tissue cannot be restored. However, adequate therapy could minimize secondary impairment of brain tissue and restore neuronal function in the so-called “penumbra region”. Apart from reopening occluded vessels, additional O2 supply is essential for survival of malfunctioning neural tissue. Breathing of 100% O2 under hyperbaric conditions, hyperbaric oxygenation (HBO), is the only method to increase the O2 concentration in tissue with impaired blood supply. Experimental as well as clinical studies have reported a positive effect of HBO therapy. Survival rate has increased under HBO therapy and neurological outcome has improved. The optimal levels of pressure as well as duration and numbers of HBO sessions need to be specified to avoid undesirable effects. Unfortunately, many questions remain unanswered before routinely recommending HBO as additional therapy in clinical practice. In this review we consider the (patho-)physiological background of HBO-therapy, the latest results of experimental and clinical studies and stress the evidence in patients with cerebrovascular disease.
Export Options
About this article
Cite this article as:
Fischer R. Bernhard, Palkovic Stefan, Holling Markus, Wolfer Johannes and Wassmann Hansdetlef, Rationale of Hyperbaric Oxygenation in Cerebral Vascular Insult, Current Vascular Pharmacology 2010; 8 (1) . https://dx.doi.org/10.2174/157016110790226598
DOI https://dx.doi.org/10.2174/157016110790226598 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Renal Nerve Ablation for the Management of Resistant Hypertension and other Disease Conditions: Benefits and Concerns
Current Vascular Pharmacology Patent Selections
Recent Patents on Food, Nutrition & Agriculture Clinical Pharmacokinetics of Systemically Administered Antimycotics
Current Clinical Pharmacology Environmental Toxicants as Extrinsic Epigenetic Factors for Parkinsonism: Studies Employing Transgenic C. elegans Model
CNS & Neurological Disorders - Drug Targets Peripartum Cardiomyopathy: Current State of Knowledge, New Developments and Future Directions
Current Cardiology Reviews Synthesis, Cytotoxicity and Molecular Docking Simulation of Novel bis-1,4-Dihydropyridines Linked to Aliphatic or Arene Core via Amide or Ester-Amide Linkages
Mini-Reviews in Medicinal Chemistry Targeting Microtubules to Inhibit Angiogenesis and Disrupt Tumour Vasculature:Implications for Cancer Treatment
Current Cancer Drug Targets Therapeutic Interventions in the Glyc(oxid)ation Pathway
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Do RAS Inhibitors Protect the Brain from Cerebral Ischemic Injury?
Current Hypertension Reviews Clinical Profile of Relaxin, a Possible New Drug for Human Use
Current Drug Safety Echocardiographic Hemodynamic Monitoring in the Critically Ill Patient
Current Cardiology Reviews Imidazole Scaffold Based Compounds in the Development of Therapeutic Drugs
Current Topics in Medicinal Chemistry Effect on Serum Uric Acid Levels of Drugs Prescribed for Indications other than Treating Hyperuricaemia
Current Pharmaceutical Design Management of Acute Aluminum Phosphide Poisoning: Has Anything Changed?
Drug Metabolism Letters Implications of Angiotensin II in Central Nervous System on Exercise Performance
Current Protein & Peptide Science CGRP-Receptor Antagonism in Migraine Treatment
CNS & Neurological Disorders - Drug Targets Drug-Induced Peripheral Neuropathy: Diagnosis and Management
Current Cancer Drug Targets Epigenetic Drugs in Cognitive Disorders
Current Pharmaceutical Design From Rapid to Delayed and Remote Postconditioning: The Evolving Concept of Ischemic Postconditioning in Brain Ischemia
Current Drug Targets Combination of Statin Plus Renin Angiotensin System Inhibition for the Prevention or the Treatment of Atherosclerotic Cardiovascular Disease
Current Pharmaceutical Design